Page last updated: 2024-11-13

nitroguanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitroguanidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nitroguanidine : An N-nitro compound that is guanidine in which one of the hydrogens is replaced by a nitro group. It can exist in distinct tautomeric forms, as 1-nitroguanidine (a nitroimine) or 2-nitroguanidine (a nitroamine); in both solid and in solution, the nitroimine form predominates. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID86287517
CHEMBL ID3187135
CHEBI ID39180
SCHEMBL ID107616
MeSH IDM0157672

Synonyms (47)

Synonym
nitroguanidine, wetted or picrite, wetted with not <20% water, by mass
ec 209-143-5
nitroguanidine or picrite, dry or wetted with <20% water, by mass [un0282] [explosive 1.1d]
nay6kwl67f ,
nitroguanidine or picrite, dry or wetted with <20% water, by mass
unii-nay6kwl67f
nitroguanidine, wetted or picrite, wetted with not <20% water, by mass [un1336] [flammable solid]
n-nitroguanidine
nsc41036
guanidine, 1-nitro-
1-nitroguanidine
picrite (the explosive)
556-88-7
nitroguanidine
picrite
guanidine, 1-nitro- (wet)
wln: wnmyzum
nsc-41036
n''-nitroguanidine
guanidine, nitro-
nitroguanidine or picrite, dry or wetted with < 20% water, by mass
hsdb 5693
un1336
n(1)-nitroguanidine
einecs 209-143-5
un0282
ai3-16306
CHEBI:39180 ,
AKOS005111009
N0206
NCGC00248865-01
cas-556-88-7
tox21_200886
dtxsid4024222 ,
NCGC00258440-01
dtxcid204222
FT-0632385
1-nitroguanidine [hsdb]
n-nitroguanidine [mi]
SCHEMBL107616
1-nitroguanidine wetted with not less than 25% water
W-105552
CHEMBL3187135
mfcd00007039
nitroguanidine (wetted with 25% water)
nitroguanidine 100 microg/ml in acetonitrile
VS-08107

Research Excerpts

Overview

Nitroguanidine (NQ) is a constituent of gas generators for automobile airbags, smokeless pyrotechnics, insecticides, propellants, and new insensitive munitions formulations applied by the military. It is currently being considered as a TNT replacement in explosive formulations.

ExcerptReferenceRelevance
"Nitroguanidine (NQ) is an emerging contaminant being used by the military as a constituent of new insensitive munitions. "( Reductive transformation of the insensitive munitions compound nitroguanidine by different iron-based reactive minerals.
Chorover, J; Field, JA; Menezes, O; Niu, XZ; Rios-Valenciana, EE; Romero, J; Root, RA; Sierra-Alvarez, R, 2022
)
2.4
"Nitroguanidine (NQ) is a constituent of gas generators for automobile airbags, smokeless pyrotechnics, insecticides, propellants, and new insensitive munitions formulations applied by the military. "( Elucidating the mechanisms associated with the anaerobic biotransformation of the emerging contaminant nitroguanidine.
Blubaum, C; Field, JA; Krzmarzick, MJ; Menezes, O; Rios-Valenciana, EE; Romero, J; Sierra-Alvarez, R, 2023
)
2.57
"Nitroguanidine (NQ) is an energetic material that is used as a key ingredient of triple-base propellants and is currently being considered as a TNT replacement in explosive formulations. "( Aerobic mineralization of nitroguanidine by Variovorax strain VC1 isolated from soil.
Ampleman, G; Halasz, A; Hawari, J; Manno, D; Perreault, NN; Thiboutot, S, 2012
)
2.12
"Nitroguanidine is a chemical of low toxicity (LD50 greater than 5 g/kg); it is quantitatively absorbed from the gastrointestinal tract, distributed throughout the body, and rapidly excreted in the urine."( The fate of nitroguanidine in the rat.
Ho, B; Kincannon, LC; Korte, DW; Simboli, PB; Tillotson, JA, 1988
)
1.38

Toxicity

ExcerptReferenceRelevance
" Without photodegradation, DNAN was more toxic (median lethal concentration [LC50] = 43 mg/L) than the other 2 constituents and it contributed predominantly to the toxicity of IMX-101 (LC50 = 206 mg/L) based on toxic units."( Aquatic toxicity of photo-degraded insensitive munition 101 (IMX-101) constituents.
Bednar, AJ; Gust, KA; Jordan, SM; Kennedy, AJ; Melby, NL; Moores, LC; Poda, AR, 2017
)
0.46
" Identification of principal toxic agents in the UV-degraded NQ product mixture remains a critical data gap."( Effect of UV-light exposure duration, light source, and aging on nitroguanidine (NQ) degradation product profile and toxicity.
Acrey, B; Amar, SK; George, GW; Gust, KA; Jones, SJ; Kennedy, AJ; Moores, LC; Rabalais, L; Zetterholm, SG, 2022
)
0.96

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of orally administered NG was 100%; the kinetics of NG in the blood was not dose dependent."( The fate of nitroguanidine in the rat.
Ho, B; Kincannon, LC; Korte, DW; Simboli, PB; Tillotson, JA, 1988
)
0.65

Dosage Studied

ExcerptRelevanceReference
" The kinetics of [14C]NG in the blood of the dosed animals was followed."( The fate of nitroguanidine in the rat.
Ho, B; Kincannon, LC; Korte, DW; Simboli, PB; Tillotson, JA, 1988
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
nitroguanidineAn N-nitro compound that is guanidine in which one of the hydrogens is replaced by a nitro group. It can exist in distinct tautomeric forms, as 1-nitroguanidine (a nitroimine) or 2-nitroguanidine (a nitroamine); in both solid and in solution, the nitroimine form predominates.
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
nitroguanidineAn N-nitro compound that is guanidine in which one of the hydrogens is replaced by a nitro group. It can exist in distinct tautomeric forms, as 1-nitroguanidine (a nitroimine) or 2-nitroguanidine (a nitroamine); in both solid and in solution, the nitroimine form predominates.
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency49.33860.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.96470.000817.505159.3239AID1159527
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1135359Ionization constant, pKa of the compound1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (10.26)18.7374
1990's2 (5.13)18.2507
2000's4 (10.26)29.6817
2010's16 (41.03)24.3611
2020's13 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.50 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index69.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (97.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]